Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 3/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.40 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18486200 | 0.89 | TYMP (0.52) | TYMPSLC29A1ADORA3DNPH1 | |
| SCHEMBL18486361 | 0.88 | PAX8 (0.39) | TYMPSLC29A1PAX8ADORA3DNPH1 | |
| SCHEMBL18486296 | 0.87 | TYMP (0.56) | TYMPSLC29A1ADORA3DNPH1TP53 | |
| SCHEMBL18486315 | 0.85 | TYMP (0.49) | TYMPSLC29A1PAX8ADORA3DNPH1 | |
| SCHEMBL18486406 | 0.85 | TYMP (0.52) | TYMPSLC29A1PAX8ADORA3DNPH1 | |
| SCHEMBL18486234 | 0.84 | TYMP (0.51) | TYMPSLC29A1ADORA3DNPH1 | |
| SCHEMBL18486386 | 0.83 | TYMP (0.52) | TYMPSLC29A1DNPH1 | |
| SCHEMBL18486247 | 0.83 | TYMP (0.52) | TYMPSLC29A1ADORA3DNPH1 | |
| SCHEMBL18486405 | 0.81 | TYMP (0.39) | TYMPSLC29A1 | |
| SCHEMBL532674 | 0.80 | TYMP (0.58) | TYMPSLC29A1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3130597-B1 | OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL | KYOWA KIRIN CO LTD (JP) | 2021-11-10 | — | — | EP | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
| EP-3130597-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | Kyowa Hakko Kirin Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | TYMP 120/4885SLC29A1 243/4885PAX8 1453/4885 |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | RNGTT, UPF1, NSUN3 | TYMP 121/4885SLC29A1 253/4885PAX8 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.